Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea

Jang, Geundoo; Lee, Sung Sook; Ahn, Jin‐Hee; Jung, Kyung Hae; Lee, Hyunjoo; Gong, Gyungyub; Kim, Hak-Hee; Ahn, Seung Do; Son, Byung Ho; Ahn, Sei‐Hyun; Kim, Sung‐Bae

doi:10.1007/s10549-011-1526-y

Cited by 23 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The IHC test is described in previous studies. 24,25 Furthermore, the ER and PR statuses were combined and denoted as HR status. For HER2 status, 0 and 11 were considered as negative and 31 as positive by IHC scores.…”

Section: Tumor Subtypes Of Breast Cancermentioning

confidence: 99%

Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: A case-case study

et al. 2014

Self Cite

View full text Add to dashboard Cite

Breast cancer is heterogeneous in clinical behavior by subtypes; however, it is unclear how this heterogeneity is related to epidemiological factors. To evaluate the differences in epidemiological factors by breast tumor subtypes, we investigated the associations of epidemiological factors between tumor subtypes in Korean women. From the Seoul Breast Cancer Study, a total of 3,058 patients with breast cancer were included in the analyses. Tumor subtypes were classified based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) statuses. The epidemiological factors of each subtype were compared through case-case analyses using multivariate a polytomous logistic regression model adjusted for age and recruiting centers. The distribution of the subtypes was as follows: 1,714 HR1 HER22 (56.0%), 414 HR1 HER21 (13.5%), 423 HR2 HER21 (13.9%) and 507 HR2 HER22 (16.6%) patients with breast cancer. There were significant differences in age, menopausal status, age at menarche, number of children, age at first full-term pregnancy (FFTP), duration of breastfeeding and duration of endogenous estrogen exposure between tumor subtypes (p < 0.05). Compared to HR1 HER22 patients, the other subtype patients showed more frequency in having more numbers of children and less frequency in having earlier menarche, later FFTP and longer endogenous estrogen exposure. Although HR2 HER21 patients were less obese, HR2 HER22 patients were younger and more obese. In conclusion, age, body mass index and reproductive factors were differentially associated with breast tumor subtypes suggesting a possible distinct etiology for tumor progression.Breast cancer is a heterogeneous disease in terms of clinical behavior. Breast tumors have been classified into intrinsic subtypes using gene expression patterns measured by microarrays.1-3 The intrinsic subtypes were explained as the clinicopathological definition based on the expression of estrogen and progesterone receptors (ER and PR), human epidermal growth factor receptor 2 (HER2) and For the basallike subtype of breast cancer, epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK 5/6) were also used as surrogates.5 These tumor subtypes have shown significant differences in their clinical features. 2,3,6 Notwithstanding the clinical heterogeneity of the tumor subtype, the etiological heterogeneity has not been established.7 Through previous epidemiological studies, several reproductive factors, such as early menarche, late menopause and late age at first full-term pregnancy (FFTP), and family history have been established as risk factors of breast cancer, and obesity has been probable as protective or a risk factor of breast cancer depending on the menopausal status. [8][9][10] Furthermore, well-known risk factors of breast cancer have been associated with the ER-positive subtype rather than the ER-negative subtype.

show abstract

Section: Tumor Subtypes Of Breast Cancermentioning

confidence: 99%

Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: A case-case study

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…TNBC is more aggressive than other breast cancer subtypes, and it is more likely to metastasize at an early stage [2, 3]. TNBC remains the hardest breast cancer subtype to treat because it is a highly heterogeneous disease and lacks effective targets for therapy [2].…”

Section: Introductionmentioning

confidence: 99%

ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1

Song

Tang

et al. 2017

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundIncreasing evidence has indicated an important role for estrogen receptor beta 1 (ERβ1) in breast cancer. However, the role of ERβ1 in the metastasis of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) and the underlying mechanisms are still unknown.MethodsStable ERβ1-expressing TNBC cell lines were generated for this study. We detected the abilities of cell migration and invasion by wound-healing and transwell assays and the expression of E-cadherin and N-cadherin by quantitative RT-PCR (qRT-PCR) and western blotting assays in TNBC cell lines. Chromatin immunoprecipitation (ChIP) analysis was performed to assess the effect of AR on ERβ1 promoter. Tumor metastasis was evaluated in vivo using a lung metastasis mouse model. Lastly, immunohistochemical expression of ERβ1 in TNBC tissues was analyzed and correlated with clinicopathological features.ResultsERβ1 suppressed the invasion and migration abilities of AR-positive TNBC cells and induced the downregulation of ZEB1. ZEB1 overexpression abrogated the increase in E-cadherin expression and the decrease in N-cadherin expression modulated by ERβ1. A lung metastasis mouse model showed that the incidence of metastasis was lower in ERβ1-expressing TNBC cells. Further, AR activation increased the anti-metastatic effect of ERβ1 in AR-positive TNBC cells, which accelerated ERβ1 transcription by functioning as a transcription factor that bound to the promoter of ERβ1. No significant change was observed in AR expression induced by ERβ1. Immunohistochemistry (IHC) analysis of TNBC clinical samples showed that ERβ1 and AR were positive in 31.7% and 23.2% of samples, respectively. ERβ1 expression was negatively correlated with ZEB1 expression and lymph node metastasis, and positively correlated with the expression of AR and E-cadherin.ConclusionOur findings suggested a potential role of ERβ1 in metastasis of AR-positive TNBC and provided novel insights into the mechanism of action of ERβ1 and the possible relationship between ERβ1 and AR.

show abstract

“…Its efficacy has been documented in several studies which suggested that postmenopausal patients, treatment with this agent can expected to yield about 20-30% objective responses. Clinical studies found that MA can improve appetite, increase food intake, promoted protein and fat synthesis of adjuvant chemotherapy in advanced breast cancer patients (Jang et al, 2011;Lara-Medina et al, 2011). MA has a certain degree of protection function of bone marrow and direct treatment of cancer role.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant chemotherapy of megestrol acetate in advanced breast cancer: A meta-analysis

Shui

Ying

Zhang

et al. 2015

Bangladesh J Pharmacol

View full text Add to dashboard Cite

Research ArticleAdjuvant chemotherapy of megesAdjuvant chemotherapy of megesAdjuvant chemotherapy of megestrol acetate in advanced breast cantrol acetate in advanced breast cantrol acetate in advanced breast cancer: A meta cer: A meta cer: A meta---analysis analysis analysis BJP IntroductionAgency for research on cancer released data show that breast cancer has been the most frequently diagnosed cancer (Jemal et al., 2006). Human epidermal growth factor receptor 2 expression is referred to as triplenegative breast cancer (TNBC), representing about 15% of all breast cancers (Adamo et al., 2012). The leading cause of cancer death among females world wide, accounting for 23% of the total cancer cases and 14% of the cancer deaths in 2008, about 458,400 people, incidence increase rate by 0.2 to 8% annually. Currently, the incidence of breast cancer annual growth rate by 3 to 4%, is higher than the global average growth rate in China (Pu et al., 2014;Zhai et al., 2015).In recent years, megestrol acetate (MA) is one artificial semi-synthetic progesterone derivative, used to endocrine treatment on breast cancer and other hormonedependent tumors (Fiorica et al., 2004). MA is applied to the non-hormone-dependent tumor treatment; has inhibitory effect of hormone dependence tumor line, especially breast cancer. At the same time, MA can improve patients' weight and appetite, alleviate gastrointestinal reaction and bone marrow suppression of adjuvant chemotherapy in advanced breast cancer (Demoor-Goldschmidt et al., 2009

show abstract

Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea

Cited by 23 publications

References 32 publications

Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: A case-case study

Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: A case-case study

ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1

Adjuvant chemotherapy of megestrol acetate in advanced breast cancer: A meta-analysis

Contact Info

Product

Resources

About